Preliminary Analysis of the Impact of Malaria Vaccine Introduction on Severe Malaria Incidence in Children Under 5 Years in the Health Districts of Edea, Japoma, and Mbanga (2020–2024)
Vorläufige Analyse der Auswirkungen der Einführung des Malariaimpfstoffs auf die Inzidenz schwerer Malaria bei Kindern unter 5 Jahren in den Gesundheitsbezirken Edea, Japoma und Mbanga (2020–2024)
Health Science Reports · 2026-11 · 9 (11)
DOI: 10.1002/hsr2.73475 ↗Auf einen Blick
In drei Gesundheitsbezirken in Kamerun stieg die Zahl schwerer Malariafälle 2024 um 11,2 %; ein Zusammenhang mit der Impfstoffabdeckung war nicht erkennbar. Die Einführung war erst im Januar 2024.
Fragestellung
Wie veränderte sich schwere Malaria bei Kindern unter 5 Jahren nach Einführung von RTS,S/AS01 in 3 Gesundheitsbezirken, und wie hing dies mit der Impfstoffabdeckung zusammen?
Methode
Retrospektive ökologische Zeittrendstudie mit Routinedaten aus DHIS 2, 2020–2024; Vergleich von 2024 mit 2023 und dem Mittelwert 2020–2023; Korrelationsanalysen zu MV3-Abdeckung und Falländerung.
Ergebnisse
Schwere Fälle stiegen 2024 um 11,2 % (6.106 auf 6.792); 10,3 % über dem Mittel 2020–2023. MV3-Abdeckung: 37,5 %, 28,8 %, 32,0 %. Pearson r = 0,41 (95 %-KI −0,92 bis 0,97; p = 0,73), Spearman ρ = 0,50 (exakter p = 1,00).
Einschränkungen
Nur 3 Bezirke; Analyse hat „virtually no power“.
Schlussfolgerung der Autor:innen
Im ersten Jahr war kein auf den Impfstoff zurückzuführender Effekt auf schwere Malaria erkennbar. Der Anstieg 2024 lag im Bereich früherer Schwankungen; die Dropout-Rate zwischen 1. und 3. Dosis war erheblich.
Kernaussagen
- Schwere Malaria 2024: +11,2 % gegenüber 2023
- Kein informativer Zusammenhang zwischen MV3-Abdeckung und Falländerung
- Ausgeprägter Dropout zwischen MV1 und MV3
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Health Science Reports, online erschienen am 04.11.2026. Verfasst von Alex Stéphane Ndjip Ndjock und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Public Health Edea Health District Littoral Region Cameroon. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background and Aims The RTS,S/AS01 malaria vaccine (MV) was introduced in Cameroon on 22 January 2024 in 42 of 200 health districts, including three in the Littoral Region (Edea, Japoma and Mbanga). This study describes early trends in severe malaria among children under 5 years of age in these three districts of the Littoral Region and explores their relation to district‐level MV coverage.
Methods
Retrospective ecological time‐trend study of routine DHIS 2 data, 2020–2024. Annual confirmed severe and uncomplicated malaria cases were described by district; 2024 was compared with 2023 and with the 2020–2023 mean. MV1–MV3 coverage and dropout were computed for 2024. MV3 coverage and the percentage change in severe cases (n = 3 districts) were explored with Pearson's correlation (exact p‐value and 95% confidence interval) and Spearman's rank correlation.
Results
Severe cases rose by 11.2% in 2024 (6,106 to 6,792) after declines of 4.7% in 2022% and 7.0% in 2023; the 2024 total was 10.3% above the 2020–2023 mean, and the rise was smaller than that between 2020 and 2021 (+ 35.8%). Increases were 14.4% in Edea, 11.5% in Japoma and 4.2% in Mbanga. MV3 coverage was 37.5%, 28.8% and 32.0%, respectively; 44.6% of children who received MV1 had not received MV3 (range 33.8%–59.3%). MV3 coverage was not informatively associated with the change in severe cases (Pearson r = 0.41, 95% CI − 0.92 to 0.97, p = 0.73; Spearman ρ = 0.50, exact p = 1.00); with three districts the analysis has virtually no power.
Conclusion
No change in severe malaria attributable to the vaccine was detectable in its first year, as expected given recent introduction and low, incomplete coverage. The 2024 increase lies within earlier year‐to‐year variation and cannot be attributed to, or against, the vaccine. Dropout between the first and third doses is substantial. Impact evaluation requires monthly time‐series analyses with comparison districts, population denominators and longer follow‐up.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Public Health Edea Health District Littoral Region Cameroon.
- Faculty of Medicine and Pharmaceutical Sciences University of Dschang Dschang Cameroon.
- Regional Technical Group for Malaria Control Littoral Regional Public Health Delegation Douala Cameroon.
- Cameroon Society of Epidemiology (Case) Yaoundé Cameroon.
- Expanded Program on Immunization Ministry of Health Yaoundé Cameroon.
- Faculty of Medicine and Pharmaceutical Sciences University of Douala Douala Cameroon.
ORCID-Profile: Alex Stéphane Ndjip Ndjock, Michaela Josee Meli, Steve Roland Souga
Zitieren
APA
Ndjip Ndjock, A. S., Meli, M. J., Ngouenko Nkakoua, N., Souga, S. R., Djomou, P. T., Ekedy-Lea, M. M., & Nyame Dipepa Nwall, E. L. (2026). Preliminary Analysis of the Impact of Malaria Vaccine Introduction on Severe Malaria Incidence in Children Under 5 Years in the Health Districts of Edea, Japoma, and Mbanga (2020–2024). Health Science Reports, 9(11). https://doi.org/10.1002/hsr2.73475
Vancouver
Ndjip Ndjock AS, Meli MJ, Ngouenko Nkakoua N, Souga SR, Djomou PT, Ekedy-Lea MM, et al. Preliminary Analysis of the Impact of Malaria Vaccine Introduction on Severe Malaria Incidence in Children Under 5 Years in the Health Districts of Edea, Japoma, and Mbanga (2020–2024). Health Science Reports. 2026;9(11). doi:10.1002/hsr2.73475
BibTeX
@article{NdjipNdjock2026,
author = {Ndjip Ndjock, Alex Stéphane and Meli, Michaela Josee and Ngouenko Nkakoua, Nina and Souga, Steve Roland and Djomou, Prince Théophile and Ekedy-Lea, Marie-Michelle and Nyame Dipepa Nwall, Esther Laura},
title = {Preliminary Analysis of the Impact of Malaria Vaccine Introduction on Severe Malaria Incidence in Children Under 5 Years in the Health Districts of Edea, Japoma, and Mbanga (2020–2024)},
journal = {Health Science Reports},
year = {2026},
volume = {9},
number = {11},
doi = {10.1002/hsr2.73475}
}
EUVIMED